MiNK Therapeutics files S-8 for 2021 equity plans

MiNK Therapeutics, Inc. filed a Form S-8 registration statement to register additional shares for its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan.

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. filed a Form S-8 registration statement to register additional shares for its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan. The company states this filing does not involve a capital-raising transaction, a public offering, or a current issuance of shares. Any shares covered may be delivered only in connection with awards or purchases under these plans in accordance with their terms. The filing incorporates by reference three prior effective S-8 registrations for the same plans and includes standard exhibits such as organizational documents, plan documents, legal opinions, auditor consent, and powers of attorney.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MiNK Therapeutics (INKT) file in this Form S-8?

MiNK Therapeutics filed a Form S-8 to register additional shares for its 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan, using General Instruction E to incorporate prior S-8 registrations by reference.

Does this MiNK Therapeutics S-8 represent a new capital-raising or public offering?

No. The company explicitly states that this filing does not relate to a capital-raising transaction, a public offering, or a current issuance of any shares.

How can the shares registered on this MiNK Therapeutics S-8 be used?

The filing states that any shares covered by this registration statement may be delivered only in connection with awards or purchases made under the 2021 Equity Incentive Plan and the 2021 Employee Stock Purchase Plan, in accordance with their terms.

Which prior registrations does MiNK Therapeutics incorporate by reference?

This Form S-8 incorporates the contents of prior MiNK Therapeutics Form S-8 registration statements with file numbers 333-281519, 333-273906, and 333-266170, each relating to the same 2021 plans.

What key exhibits are included with MiNK Therapeutics' S-8?

The exhibits include MiNK Therapeutics' Amended and Restated Certificate of Incorporation, a Certificate of Amendment, Amended and Restated Bylaws, the full text of the 2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan, a legal opinion from Latham & Watkins LLP, a consent from KPMG LLP, and powers of attorney.

Who signed the MiNK Therapeutics Form S-8 and in what capacities?

The registration statement was signed on behalf of MiNK Therapeutics by Jennifer S. Buell, Ph.D., as President, Chief Executive Officer and Director, and also signed by the Treasurer and Principal Accounting and Financial Officer Christine M. Klaskin, along with the Chairman and other directors under a power of attorney.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:28 PM Learn about SEC filing dates

As filed with the Securities and Exchange Commission on August 14, 2025

Registration No. 333-   

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

MiNK Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		82-2142067
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
149 Fifth Avenue, Suite 500, New York, NY		10010
(Address of Principal Executive Offices)		(Zip Code)

MiNK Therapeutics, Inc. 2021 Equity Incentive Plan

MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan

(Full titles of the plans)

Jennifer S. Buell, Ph.D.

President, Chief Executive Officer and Director

MiNK Therapeutics, Inc.

149 Fifth Avenue, Suite 500

New York, NY 10010

(Name and address of agent for service)

(212) 994-8250

(Telephone number, including area code, of agent for service)

Please send a copy of all communications to:

Wesley Holmes, Esq.

Latham & Watkins LLP

200 Clarendon Street

Boston, MA 02116

(617) 948-6060

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		☐		Accelerated filer		☐
Non-accelerated filer		☒		Smaller reporting company		☒
				Emerging growth company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

Explanatory Note

This Registration Statement on Form S-8, relating to the 2021 Equity Incentive Plan (the “2021 EIP”) of MiNK Therapeutics, Inc. (the “Registrant”) and the 2021 Employee Stock Purchase Plan of the Registrant (the “ESPP”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. This filing does not relate to a capital-raising transaction, a public offering, or current issuance of any shares. Any shares covered by this Registration Statement may be delivered only in connection with awards or purchases made under these plans in accordance with their terms.

Accordingly, pursuant to General Instruction E to Form S-8, this Registration Statement incorporates by reference the contents of the Registration Statements on Form S-8 and any amendments thereto, File Nos. 333-281519, 333-273906 and 333-266170, filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2024, August 11, 2023 and July 15, 2022 by the Registrant, respectively, relating to the 2021 EIP and the ESPP.

Item 8. Exhibits.

Exhibit
4.1		Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 20, 2021 and incorporated herein by reference).
4.2		Certificate of Amendment to the Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on January 21, 2025 and incorporated herein by reference).
4.3		Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 20, 2021 and incorporated herein by reference).
4.4		MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (previously filed as Exhibit 10.6 to the registration statement on Form S-1/A filed on October 12, 2021 (File No. 333-259503) and incorporated herein by reference).
4.5		MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan (previously filed as Exhibit 10.7 to the registration statement on Form S-1/A filed on October 12, 2021 (File No. 333-259503) and incorporated herein by reference).

5.1		Opinion of Latham & Watkins LLP, counsel to the Registrant*
23.1		Consent of KPMG LLP*
23.2		Consent of Latham & Watkins LLP (included in the opinion filed as Exhibit 5.1)*
24.1		Powers of Attorney (included on the signature page in Part II)*
107		Filing Fee Table*

* Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, NY, on this 14th day of August, 2025.

MINK THERAPEUTICS, INC.
By:		/s/ Jennifer S. Buell, Ph. D
		Name: Jennifer S. Buell, Ph. D.
		Title: President, Chief Executive Officer and Director

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Jennifer S. Buell, Ph.D. and Christine M. Klaskin, and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

* * * *

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

Signature		Title		Date
/s/ Jennifer S. Buell, Ph.D. Jennifer S. Buell, Ph.D.		President, Chief Executive Officer and Director (Principal Executive Officer)		August 14, 2025
/s/ Christine M. Klaskin Christine M. Klaskin		Treasurer (Principal Accounting and Financial Officer)		August 14, 2025
/s/ Garo H. Armen, Ph.D. Garo H. Armen, Ph.D.		Chairman of the Board of Directors		August 14, 2025
/s/ Peter Behner Peter Behner		Director		August 14, 2025
/s/ Brian Corvese Brian Corvese		Director		August 14, 2025
/s/ Robert Kadlec Robert Kadlec		Director		August 14. 2025
/s/ Barbara Ryan Barbara Ryan		Director		August 14, 2025
/s/ Ulf Wiinberg Ulf Wiinberg		Director		August 14, 2025